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Abstract Suppressor of cytokine signaling-1 (SOCS1) was
identi¢ed as the negative regulator of Janus kinase (JAK) and
signal transducer and activator of transcription (STAT) signal
transduction pathway. However, the kinetics and control mech-
anism of the pathway have not yet been fully understood. We
have developed the computer simulation of the JAK/STAT
pathway. Without nuclear phosphatase, SOCS1’s binding to
JAK did not cause the decrease in nuclear phosphorylated
STAT1. However, without SH2 domain-containing tyrosine
phosphatase 2 (SHP-2) or cytoplasmic phosphatase, it did. So
nuclear phosphatase is considered to be the most important in
this system. By changing parameters of the model, dynamical
characteristics and control mechanism were investigated.
, 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Recently, many proteins and protein interactions in signal
transduction pathways have been identi¢ed. Since the phos-
phorylation of serine/threonine or tyrosine residues is a key
reaction in the signal transduction pathway, protein phospha-
tases must have an essential role similarly to protein kinases.
However, protein phosphatases have been paid less attention,
compared to protein kinases, especially from the dynamical
point of view.
In the Janus kinase (JAK) and and signal transducer and
activator of transcription (STAT) signal transduction path-
way, which transduces the class I/II cytokine receptor signals
and has been considerably studied [1,2], SH2 domain-contain-
ing tyrosine phosphatase 2 (SHP-2) was identi¢ed as a phos-
phatase for the dephosphorylation of receptors and JAK, and
its role in the pathway has been studied [3,4]. The phosphor-
ylated STAT homo- or hetero-dimers were translocated to the
nucleus and worked as the transcription factors [5]. But the
behavior of the STAT after the translocation and the control
mechanism of its nuclear concentration have not been dis-
cussed. The JAK-binding protein [JAB/suppressor of cytokine
signaling-1 (SOCS1)] inhibits JAK signaling in cells. We dem-
onstrated that JAB speci¢cally binds to the tyrosine residue in
the activation loop of JAKs whose phosphorylation is re-
quired for the activation of kinase activity. The SOCS1 SH2
domain and N-terminal 12 amino acid region (kinase inhibi-
tory region) is required for the binding to JAKs and the in-
hibition of its activity. Gene disruption studies demonstrated
that JAB/SOCS1 negatively regulates interferon-Q (IFN-Q) sig-
naling [6^10]. However, the control mechanism of this system
has not been clari¢ed. Furthermore, although a nuclear phos-
phatase was reported to be necessary for the JAK/STAT path-
way [11] and identi¢ed recently [12], its role in the pathway
has not been fully understood.
In order to investigate the control mechanism and the fac-
tors in£uencing the kinetics of JAK/STAT pathway, we have
developed a computer simulation of the JAK/STAT signal
transduction pathway. The IFN-Q pathway in liver cells was
selected as a typical example. Our analysis indicates that nu-
clear phosphatase is the most important phosphatase in this
system. And our analysis also shows the stability of the time
course of active transcription factors against the addition of
STAT1, receptor, and JAK proteins to the system. The reason
why induced protein is used for the feedback control is also
investigated.
2. Model description
The kinetic scheme presented in Fig. 1 forms the basis for the
computational analysis of the JAK/STAT signaling network. In step
1, JAK binds to the intracellular domain of the IFN-Q receptor
(IFNR) and forms the IFNR^JAK complex (designated as RJ in
the kinetic scheme). Although JAK1 and JAK2 bind to IFNR, both
JAK’s are treated as JAK in this model for simplicity. IFN-Q binds to
the extracellular domain of the RJ complex and forms the IFN-Q^
IFNR^JAK complex (designated as IFNRJ) (step 2). IFN binding
drives the association of two receptor monomers into a receptor dimer
(IFNRJ2) (step 3). The dimerization of the RJ complex leads to the
phosphorylation of several tyrosine residues by JAK (step 4) [1,2],
yielding a form as IFNRJ2*. The STAT1 binds to IFNRJ2* and is
phosphorylated by JAK (step 5) [1,2,13]. The phosphorylated STAT1
forms a homo-dimer (step 6) [14]. The phosphorylated dimers of
STAT1 are translocated to the nucleus (step 7) and work as the tran-
scription factors (step 8) [5]. The SOCS1 is induced by JAK/STAT
pathway (step 9). The SOCS1 binds to the activated receptor^JAK
and inhibits its kinase activity (step 10) [6^10].
The SHP-2 is known to be a phosphatase for the RJ complex[3].
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However, phosphatases for phosphorylated STATs in the cytoplasm
and the nucleus have been paid less attention to, although nuclear
phosphatase was reported to have an important role in JAK/STAT
pathway [11] and identi¢ed recently [12]. These phosphatases are as-
sumed as PPX and PPN for phosphatases in the cytoplasm and the
nucleus, respectively. Although nuclear STAT1 protein tyrosine phos-
phatase was identi¢ed as TC45 [12], it is called as PPN in this model.
The binding of STAT1, SHP-2, and SOCS1 to IFNRJ2* are not
competitive. All binding forms are considered in this model, and
SHP-2 works even if the other proteins bind to IFNRJ2*.
In this kinetic analysis, Michaelis^Menten equation is not used,
because in the signal transduction pathway the condition that the
substrate concentration is much larger than the enzyme is not usually
satis¢ed. All reactions are represented by mass-action kinetics. A cell
is divided into two compartments, the cytoplasm and the nucleus. The
phosphorylated STAT1 dimers were reported to be translocated to the
nucleus and dephosphorylated STAT1 monomer was transported
from the nucleus to the cytoplasm [15]. Other transports through
the nuclear membrane except mRNA’s transport to the cytoplasm
are ignored. The translocation rate of STAT protein and mRNA is
approximated to be proportional to their concentrations. The tran-
scription rate depends on the concentration of the active transcription
factors and has maximal rate because of the limited number of RNA
polymerase complexes. The transcription rate vt is approximated by
the following equation [16]:
vt ¼ Vmax½TrK tr þ ½Tr
where [Tr], Vmax, and Ktr denote the concentration of the active tran-
scription factor, the maximal transcription rate, and the constant,
respectively. Because the translation rate is not a rate-limit step, it
is approximated to be proportional to the mRNA concentration in
the cytoplasm.
Since SOCS1 was reported to be degraded by the proteasome [17]
and mRNA is not stable in the cytoplasm, the degradation reaction of
SOCS1 and mRNA are included in this kinetic scheme, and are ap-
proximated to be proportional to their concentrations.
The dissociation and kinetic constants and the protein concentra-
tion were set based on the experimental results. The parameter values
were set in step order. The dissociation constant for IFN-Q and IFNR
was set to values similar to the dissociation constants of other cyto-
kines (0.1^1 nM). Then, the binding and kinetic constants for recep-
tor^JAK phosphorylation were set to ¢t the JAK phosphorylation to
the experimental results [18]. And then, the binding constants and
kinetic constants for STAT phosphorylation and STAT translocation
were set to ¢t those to the STAT phosphorylation and distribution
change of green £uorescent protein^STAT [5]. The dissociation con-
stants of SOCS1 and IFNRJ2* were set based on the experimental
results [8,19]. Detailed chemical reactions and their parameters are
described in Appendix.
These reactions are described in the di¡erential equations and
solved mathematically by using Runge^Kutta^Gill method. The sim-
ulation program was written in C by us, using commonly used
Runge^Kutta^Gill subroutine.
3. Results and discussion
The cytokine binding to its receptor induces receptor-dimer-
ization and autophosphorylation of receptor and receptor-
bound JAK. The phosphorylated JAK was detected at 15
min after the exposure to IFN and reached a maximum at
about 30 min. STATs are phosphorylated by JAK, and make
homo- or hetero-dimers. The phosphorylated STATs were
detected at 30 min. and reached a maximum between 1 and
2 h, and then decreased by the inhibition of induced SOCS1.
Fig. 2 demonstrates that the simulated time course shows the
above characteristics. In SOCS1 knock-out cells, the phos-
phorylated STAT1 were kept in a high concentration. The
simulated time course also shows the accumulation of the
phosphorylated STAT1 in the nucleus (Fig. 2F), and was
consistent with the reported experimental data [18]. The phos-
phorylation rate of JAKs and STATs is dependent on the cell
types and cytokines. Cells stimulated by IFN showed the
above time courses [20]. Cells stimulated by other cytokines
(e.g. interleukin-2) showed faster time courses [20]. The model
having more receptors and JAKs as well as that with faster
phosphorylation rate by JAK showed faster time courses
(data not shown).
This system involves three phosphatase, SHP-2 and two
phosphatases for STAT1. The dependency of the time course
of phosphorylated STAT1 dimers in the nucleus (STAT1*Dn)
on the phosphatase concentration was investigated in order to
evaluate their role in this system. Fig. 3A^C shows the time
course of STAT1*Dn for various PPN (A), PPX (B), and
SHP-2 (C) concentrations. The changes in PPN concentration
caused the most considerable changes in the time course
among the three phosphatases. Fig. 3D shows the dependency
of peak concentration and Fig. 3E shows the steady-state
concentration of STAT1*Dn. In the low concentration of
PPN, STAT1*Dn did not decrease after the peak, and almost
all STAT1 were kept as active transcription factors in the
nucleus, which was similar to the time course in the SOCS1
knock-out cells. However, in the low concentration of PPX
and SHP-2 the time courses of STAT1*Dn were similar to
that under the normal condition. In the high concentration
of these three phosphatases, the signal transduction of JAK/
STAT pathway was inhibited. These results indicate that PPN
is the most important phosphatase in the inhibitory action of
SOCS1.
The concentration of STAT1*Dn is determined by the bal-
ance of STAT1*D’s in£ux to the nucleus and its e¥ux. With-
out SOCS1 production (Fig. 2L,N), the in£ux exceeds the
e¥ux until 1.5 h, and the STAT1 is accumulated in the nu-
cleus, and then the in£ux and the e¥ux are balanced. With
SOCS1 inhibition (Fig. 2K,M), the phosphorylation of
STAT1 is inhibited by the binding of SOCS1 to JAK and
the in£ux decreases. Since the e¥ux exceeds the in£ux from
1 to 4 h, STAT1*Dn decreases after 1 h. In order to decrease
STAT1*Dn, not only the decrease in the in£ux but also the
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Fig. 1. Schematic representation of the computer simulation of
JAK/STAT signal transduction pathway. Numbers in parentheses
denote the number of reaction steps.
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e¥ux is needed. The e¥ux reactions consist of the dephos-
phorylation in the nucleus and the translocation from the
nucleus. Because the dephosphorylation in the nucleus is cat-
alyzed by PPN, PPN is necessary for the e¥ux and more
important than the other phosphatases. Without PPN, the
binding of SOCS1 to JAK did not cause the decrease in
STAT1*Dn (Fig. 3A).
The stability of responses (the peak and steady state con-
centration of active transcription factors (STAT1*Dn)) was
investigated. Responses with various initial concentrations
or parameter values were compared. If the phosphorylation
reactions were decelerated, which corresponds to the decreases
in initial STAT1 (Fig. 4A,B), receptor, and JAK (Fig. 4C), or
the increases in dissociation constant between them (data not
shown), the responses decreased as the phosphorylation rate
decreased. On the contrary, even if the phosphorylation reac-
tions were accelerated (Fig. 4A, bold lines), the responses were
similar to that under the normal condition. Because the peak
concentration of STAT1*Dn under the normal condition is
close to the maximum, the peak values are changed a little
by the addition of STAT1. The steady state concentration is
determined by the balance of the in£ux and e¥ux. The in£ux
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Fig. 2. Simulated time course of JAK/STAT activation in liver cells over 8 h continuous exposure to IFN-Q in normal cells (A,C,E,G,I,K,M)
and SOCS1 knock-out cells (B,D,F,H,J,L,N). The time course of activated IFNRJ (A,B), dephosphorylated STAT1 in the cytoplasm (C,D),
STAT1*Dn (E,F), mRNA in the cytoplasm (G,H), SOCS1 in the cytoplasm (I,J), STAT1 in£ux to the nucleus (K,L), and STAT1 e¥ux from
the nucleus (M,N).
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in the steady state is determined by the concentration of free
(not bound with SOCS1) JAK^receptor complexes. So the
increase in the single factor or the a⁄nity between them
does not induce the e⁄cient increase in the complex concen-
tration. Fig. 4B,C shows that the steady state concentration of
STAT1*Dn does not change by the addition of STAT, JAK,
and receptor. If the two of those factors simultaneously in-
crease (Fig. 4D), the initial concentrations of both receptor
and JAK increase), the steady state concentration of
STAT1*Dn increases. The responses of JAK/STAT signal
transduction pathway are stable against the addition of
STAT1, JAK, and receptor.
Why JAK/STAT pathway is controlled by an induced pro-
tein? In the signal transduction pathway, the transduced sig-
nal must be controlled to have adequate size and duration. If
phosphatase activity is stronger than kinase activity, a tran-
sient signal is formed [21]. In JAK/STAT pathway, a kinase
activity is stronger than a phosphatase activity, since phos-
phorylated STAT1 was accumulated in the nucleus in SOCS1
knock-out cells. The feedback control by activated protein in
the pathway is another candidate of the control scheme. The
Ras^MAP kinase cascade was reported to be controlled by
such a scheme [22], the activation of Ras was inhibited by the
activated ERK. In order to investigate the validity of feed-
back control of activated protein, the kinetics of a tentative
pathway shown in Fig. 5A was simulated. In this tentative
model, phosphorylated STAT1 dimers are assumed to bind
to JAK kinases and inhibit them. This scheme showed no
transient signals (Fig. 5B). Since inhibitory binding occurs
without time-lag, the concentration of active transcription
factors shows a simple time course of the saturation and
no transient peak. Furthermore, since the concentration of
STAT1 dimers in the cytoplasm is low because of the trans-
location to the nucleus, the inhibitory action by STAT1
dimers will not be e¡ective. On the contrary, an induced pro-
tein (SOCS1) showed transient kinetics under various condi-
tions (Fig. 5C shows the time course with several dissociation
constants), since the inhibitory factors appear with a time-lag.
In the MAPK cascade active ERK appears with time-lag,
therefore feedback control by the activated existing factors
is useful. The Smad pathway is another pathway of one-step
activation of transcription factors, it is also controlled by the
induced inhibitory Smad (I-Smad) [23].
4. Conclusions
Through a quantitative analysis of a computer simulation
of JAK/STAT signal transduction pathway in liver cells, we
have presented the SOCS1 inhibitory mechanism and the im-
portance of a nuclear phosphatase. Simulation of SOCS1 3/3
was consistent with the reported experimental data [18]. In the
JAK/STAT pathway, SHP-1 or SHP-2 has been studied as a
negative regulator. However, from the simulation result, a
nuclear phosphatase (PPN in our model) is the most impor-
tant phosphatase in this system. Although the signal trans-
duction was inhibited by the high concentration of SHP-2,
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that without SHP-2 was similar to that under the normal
condition. However, the signal transduction without PPN
was similar to that in SOCS1 knock-out cells.
The further addition of receptor, JAK, or STAT1 did not
cause the increase in the active transcription factors, especially
in the steady state. The feedback control of the system can
keep the signal size and duration against the addition of ac-
tuator proteins.
The JAK/STAT and Smad pathways share a similar scheme
with one-step activation of transcription factors. Since the
inhibition by the activated protein themselves is not e¡ective,
these systems are controlled by induced inhibitory proteins,
SOCS1 or I-Smad. The duration of the signal is one to several
hours because a protein synthesis takes about 1 h.
The merit of the model study is to be able to investigate the
role of any factors and any parameters in the system by the
simulation with various values. We investigated the control
mechanism by changing the model.
Appendix. Chemical reactions and their parameter values
First and second order rate constants are expressed in units
of second31 and 106 molar31 second31, respectively. The dis-
sociation constants for binding reactions are also written in
parentheses in units of nM. Initial concentrations of proteins
are expressed in units of nM.
[R]+[JAK]H[RJ] k1 = 100, k31 = 0.05 (kd1 = 0.5)
[IFN]+[RJ]H[IFNRJ] k2 = 20, k32 = 0.02 (kd2 = 1)
2[IFNRJ]H[IFNRJ2] k3 = 40, k33 = 0.2 (kd3 = 5)
[IFNRJ2]C[IFNRJ2*] k4 = 0.005
[IFNRJ2*]+[STAT1c]H[IFNRJ2*-STAT1c] k5 = 8, k35 = 0.8
(kd5 = 100)
[IFNRJ2*-STAT1c]C[IFNRJ2*]+[STAT1c*] k6 = 0.4
[IFNRJ2*]+[STAT1c*]H[IFNRJ2*-STAT1c*] k7 = 5, k37 =
0.5 (kd7 = 100)
2[STAT1c*]H[STAT1c*-STAT1c*] k8 = 20, k38 = 0.1 (kd8 = 5)
[IFNRJ2*]+[SHP-2]H[IFNRJ2*-SHP-2] k9 = 1, k39 = 0.2
(kd9 = 200)
[IFNRJ2*-SHP-2]C[IFNRJ2]+[SHP-2] k10 = 0.003
[PPX]+[STAT1c*]H[PPX-STAT1c*] k11 = 1, k311 = 0.2
(kd11 = 200)
[PPX-STAT1c*]C[PPX]+[STAT1c] k12 = 0.003
[PPX]+[STAT1c*-STAT1c*]H[PPX-STAT1c*-STAT1c*] k11,
k311, (kd11)
[PPX-STAT1c*-STAT1c*]C[PPX]+[STAT1c-STAT1c*] k12
[STAT1c]+[STAT1c*]H[STAT1c-STAT1c*] k13 = 0.0002,
k313 = 0.2 (kd13 = 1000000)
[STAT1c*-STAT1c*]C[STAT1n*-STAT1n*] k14 = 0.005
2[STAT1n*]H[STAT1n*-STAT1n*] k7, k37, (kd7)
[PPN]+[STAT1n*]H[PPN-STAT1n*] k15 = 1, k315 = 0.2
(kd15 = 200)
[PPN-STAT1n*]C[PPN]+[STAT1n] k16 = 0.005
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Fig. 4. Dependency on the STAT1, receptor, and JAK concentration. A: The time course of STAT1*Dn for various STAT1 concentrations
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(8 h, b) of STAT1*Dn on the STAT1 concentration. C: The dependency on the receptor (peak, a ; 8 h, b)and JAK concentration (peak, E ;
8 h, F). D: The dependency on receptor^JAK concentration (both receptor and JAK concentrations are changed; peak, a ; 8 h, b).
FEBS 26886 6-1-03
S. Yamada et al./FEBS Letters 534 (2003) 190^196194
[PPN]+[STAT1n*-STAT1n*]H[PPN-STAT1n*-STAT1n*]
k15, k315, (kd15)
[PPN-STAT1n*-STAT1n*]C[PPN]+[STAT1n-STAT1n*] k16
[STAT1n]+[STAT1n*]H[STAT1n-STAT1n*] k13, k313, (kd13)
[STAT1n]C[STAT1c] k17 = 0.05
d[mRNAn]/dt= k18a[STAT1n*-STAT1n*]/(k18b+[STAT1n*-
STAT1n*]) k18a = 0.01 nM/s, k18b = 400 nM
[mRNAn]C[mRNAc] k19 = 0.001
d[SOCS1]/dt= k20[mRNAc] k20 = 0.01
[SOCS1]+[IFNRJ2*]H[SOCS1-IFNRJ2*] k21 = 20, k321 = 0.1
(kd21 = 5)
d[mRNAc]/dt= -k22[mRNAc] k22 = 0.0005
d[SOCS1]/dt= -k23[SOCS1] k23 = 0.0005
[STAT1c]+[SOCS1-IFNRJ2*]H[SOCS1-IFNRJ2*-STAT1c]
k5, k35, (kd5)
[SHP-2]+[SOCS1-IFNRJ2*-STAT1c]H[SOCS1-IFNRJ2*-
STAT1c-SHP-2] k9, k39, (kd9)
[SOCS1-IFNRJ2*-STAT1c-SHP-2]C[SOCS1]+[IFNRJ2]+
[STAT1c]+[SHP-2] k10
[SOCS1-IFNRJ2*-STAT1c-SHP-2]C[IFNRJ2*-STAT1c-
SHP-2] k23
[R]0 = 12, [JAK]0 = 12, [STAT1c]0 = 1000, [SHP-2]0 = 100,
[PPX]0 = 50, [PPN]0 = 60
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The time course of STAT1*Dn in the tentative scheme shown in panel A with various dissociation constants (1^100 nM) of phosphorylated
STAT1 dimers and JAK. C: The time course of STAT1*Dn in the normal model shown in Fig. 1 with various dissociation constants (0.5^50
nM) of SOCS1 and JAK.
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